29
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology

      research-article
      , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , On behalf of the EUROASPIRE Investigators
      Cardiovascular Diabetology
      BioMed Central
      Coronary artery disease, Type 2 diabetes, Secondary prevention, Management, Guideline adherence, Blood lipids, Blood pressure, Glycaemic control

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines.

          Methods

          A total of 6187 patients (18–80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabetes) or the results of an oral glucose tolerance test and HbA1c (no diabetes or newly diagnosed diabetes) were investigated in EUROASPIRE IV including patients in 24 European countries 2012–2013. The patients were interviewed and investigated in order to enable a comparison between their actual risk factor control with that recommended in current European management guidelines and the outcome in previously conducted surveys.

          Results

          A total of 2846 (46 %) patients had no diabetes, 1158 (19 %) newly diagnosed diabetes and 2183 (35 %) previously known diabetes. The combined use of all four cardioprotective drugs in these groups was 53, 55 and 60 %, respectively. A blood pressure target of <140/90 mmHg was achieved in 68, 61, 54 % and a LDL-cholesterol target of <1.8 mmol/L in 16, 18 and 28 %. Patients with newly diagnosed and previously known diabetes reached an HbA1c <7.0 % (53 mmol/mol) in 95 and 53 % and 11 % of those with previously known diabetes had an HbA1c >9.0 % (>75 mmol/mol). Of the patients with diabetes 69 % reported on low physical activity. The proportion of patients participating in cardiac rehabilitation programmes was low (≈40 %) and only 27 % of those with diabetes had attended diabetes schools. Compared with data from previous surveys the use of cardioprotective drugs had increased and more patients were achieving the risk factor treatment targets.

          Conclusions

          Despite advances in patient management there is further potential to improve both the detection and management of patients with diabetes and coronary artery disease.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: not found
          • Article: not found

          Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Waist circumference as a measure for indicating need for weight management.

            To test the hypothesis that a single measurement, waist circumference, might be used to identify people at health risk both from being overweight and from having a central fat distribution. A community derived random sample of men and women and a second, validation sample. North Glasgow. 904 men and 1014 women (first sample); 86 men and 202 women (validation sample). Waist circumference, body mass index, waist:hip ratio. Waist circumference > or = 94 cm for men and > or = 80 cm for women identified subjects with high body mass index (> or = 25 kg/m2) and those with lower body mass index but high waist:hip ratio (> or = 0.95 for men, > or = 0.80 women) with a sensitivity of > 96% and specificity > 97.5%. Waist circumference > or = 102 cm for men or > or = 88 cm for women identified subjects with body mass index > or = 30 and those with lower body mass index but high waist:hip ratio with a sensitivity of > 96% and specificity > 98%, with only about 2% of the sample being misclassified. Waist circumference could be used in health promotion programmes to identify individuals who should seek and be offered weight management. Men with waist circumference > or = 94 cm and women with waist circumference > or = 80 cm should gain no further weight; men with waist circumference > or = 102 cm and women with waist circumference > or = 88 cm should reduce their weight.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.

              The aim of the European Action on Secondary and Primary Prevention by Intervention to Reduce Events III (EUROASPIRE III) survey was to determine whether the Joint European Societies' guidelines on cardiovascular prevention are being followed in everyday clinical practice and to describe the lifestyle, risk factor and therapeutic management in patients with coronary heart disease (CHD) in Europe. The EUROASPIRE III survey was carried out in 2006-2007 in 76 centres from selected geographical areas in 22 countries in Europe. Consecutive patients, with a clinical diagnosis of CHD, were identified retrospectively and then followed up, interviewed and examined at least 6 months after their coronary event. Thirteen thousand nine hundred and thirty-five medical records (27% women) were reviewed and 8966 patients were interviewed. At interview, 17% of patients smoked cigarettes, 35% were obese and 53% centrally obese, 56% had a blood pressure >or=140/90 mmHg (>or=130/80 in people with diabetes mellitus), 51% had a serum total cholesterol >or=4.5 mmol/l and 25% reported a history of diabetes of whom 10% had a fasting plasma glucose less than 6.1 mmol/l and 35% a glycated haemoglobin A1c less than 6.5%. The use of cardioprotective medication was: antiplatelets 91%; beta-blockers 80%; angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers 71%; calcium channel blockers 25% and statins 78%. The EUROASPIRE III survey shows that large proportions of coronary patients do not achieve the lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention. Wide variations in risk factor prevalences and the use of cardioprotective drug therapies exist between countries. There is still considerable potential throughout Europe to raise standards of preventive care in order to reduce the risk of recurrent disease and death in patients with CHD.
                Bookmark

                Author and article information

                Contributors
                +46706971371 , vivecagyberg@gmail.com
                Dirk.DeBacquer@UGent.be
                guy.debacker@ugent.be
                c.jennings@imperial.ac.uk
                k.kotseva@imperial.ac.uk
                linda.mellbin@ki.se
                Oliver.Schnell@lrz.uni-muenchen.de
                jaakko.tuomilehto@thl.fi
                d.wood@imperial.ac.uk
                Lars.Ryden@ki.se
                Philippe.amouyel@pasteur-lille.Fr
                jan.bruthans@seznam.cz
                almudenacastroconde@yahoo.es
                renata.cifkova@ftn.cz
                j.deckers@erasmusmc.nl
                johan.desutter@ugent.be
                mdilic@bih.net.ba
                marinadolzhenko@mail.ru
                a.a.erglis@stradini.lv
                zlatko.fras@telemach.net
                dgaita@cardiologie.ro
                ngotcheva@abv.bg
                igoudev@cc.uoi.gr
                E_Heuschma_P@klinik.uni-wuerzburg.de
                alius@cardio.it
                seppo.lehto@varkaus.fi
                draganl1@sbb.rs
                d.milicic@mail.inet.hr
                David.Moore@amnch.ie
                evnicor@cytanet.com.cy
                oganov@gnicpm.ru
                andrzej.pajak@uj.edu.pl
                NPogosova@gnicpm.ru
                zreiner@kbc-zagreb.hr
                Martin.Stagmo@skane.se
                Stoerk_S@medizin.uni-wuerzburg.de
                lalet@hacettepe.edu.tr
                dule@blic.net
                Journal
                Cardiovasc Diabetol
                Cardiovasc Diabetol
                Cardiovascular Diabetology
                BioMed Central (London )
                1475-2840
                1 October 2015
                1 October 2015
                2015
                : 14
                : 133
                Affiliations
                [ ]Cardiology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden
                [ ]Centre for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
                [ ]European Society of Cardiology, Les Templiers, 2035 route des Colles, CS 80179 BIOT, 06903 Sophia Antipolis Cedex, France
                [ ]Department of Public Health, Ghent University, Ghent, Belgium
                [ ]Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, London, UK
                [ ]Forschergruppe Diabetes e.V. at the Helmholtz Center, Munich, Germany
                [ ]Centre for Vascular Prevention, Danube-University Krems, Krems, Austria
                [ ]Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
                [ ]Instituto de Investigacion Sanitaria del Hospital Universario LaPaz (IdiPAZ), Madrid, Spain
                [ ]Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia
                [ ]Institut Pasteur de Lille, Inserm U744, Université Lille Nord de France, 1 rue du Professeur Calmette B.P. 245, 59019 Lille, France
                [ ]Center for Cardiovascular Prevention, 1st School of Medicine, Charles University and Thomayer Hospital, Vídeňská 800, 140 59 Prague, Czech Republic
                [ ]Cardiac Rehabilitation Unit, Cardiology Department, Hospital Universitario La Paz, Madrid, Spain
                [ ]Thoraxcenter’s Department of Cardiology, Dr Molewaterplein 50, 3000 DR Rotterdam, The Netherlands
                [ ]Department of Internal Medicine, University of Ghent, De Pintelaan 185, 9000 Ghent, Belgium
                [ ]Clinical Center University of Sarajevo, Bolnička 25, 71000 Sarajevo, Bosnia and Herzegovina
                [ ]Department of Cardiology of Shupyk’s Medical Academy of Postgraduate Education, 9 Dorohozhyts’ka str, Kiev, 04112 Ukraine
                [ ]University of Latvia, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, Riga, 1002 Latvia
                [ ]Preventive Cardiology Unit, Division of Internal Medicine, University Medical Centre Ljubljana, Zaloška 7, 1525 Ljubljana, Slovenia
                [ ]Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia
                [ ]Institutul de Boli Cardiovasculare, Universitatea de Medicina si Farmacie “Victor Babes”, Timisoara, Romania
                [ ]Department of Cardiology, National Heart Hospital, 65, Konyovitsa, 1309 Sofia, Bulgaria
                [ ]Cardiology Department of Medical School, University of Ioannina, Ioannina, Greece
                [ ]Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany
                [ ]Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany
                [ ]Clinical Trial Center Würzburg, University Hospital Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
                [ ]Clinic of Cardiovascular Diseases of Vilnius University, Santariskiu 2, 08661 Vilnius, Lithuania
                [ ]Heart and Vascular Medicine of Vilnius University Hospital Santariskiu Clinics, Santariskiu 2, 08661 Vilnius, Lithuania
                [ ]Kuopio University Hospital, Rakennus 5/6. Kerros, Puijonlaaksontie 2, 70210 Kuopio, Finland
                [ ]Clinic for Internal Medicine Intermedica, Jovana Ristica 20/2, 18000 Nis, Serbia
                [ ]University of Zagreb School of Medicine and University Hospital Centre Zagreb, Kispaticeva 12, HR-10000 Zagreb, Croatia
                [ ]The Adelaide and Meath Hospital, Tallaght, Dublin 24, Ireland
                [ ]University of Nicosia Medical School, Nicosia General Hospital, 2029 Strovolos, Nicosia, Cyprus
                [ ]National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, 10 Petroverigsky per, 101990 Moscow, Russia
                [ ]Department of Epidemiology and Population Studies, Faculty of Health Sciences, Jafiellonian University Medical College, Grzegórzecka 20, 31-531 Cracow, Poland
                [ ]Federal Health Centre and Department of Chronic Noncommunicable Diseases Prevention, National Research Centre for Preventive Medicine, 10 Petroverigsky per, 101953 Moscow, Russia
                [ ]University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia
                [ ]Department of Heart failure and Valve Disease, Skåne University Hospital, Lund, Sweden
                [ ]Comprehensive Heart Failure Centre and Department of Medicine I, University of Würzburg, Straubmühlweg 2a, 97078 Würzburg, Germany
                [ ]Hacettepe University, 06690 Ankara, Turkey
                [ ]Centre for Medical Research, School of Medicine, University of Banja Luka, Vuka Karadzica 6, 78000 Banja Luka, Republic of Srpska Bosnia and Herzegovina
                Article
                296
                10.1186/s12933-015-0296-y
                4591740
                26427624
                4bd805c4-23ac-4fa4-b197-2c3994fc0202
                © Gyberg et al. 2015

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 29 July 2015
                : 24 September 2015
                Categories
                Original Investigation
                Custom metadata
                © The Author(s) 2015

                Endocrinology & Diabetes
                coronary artery disease,type 2 diabetes,secondary prevention,management,guideline adherence,blood lipids,blood pressure,glycaemic control

                Comments

                Comment on this article